Main Uses of Enjomin

Enjomin is an antihistamine medication primarily used for the prevention and symptomatic relief of nausea, vomiting, and dizziness associated with motion sickness. It contains the active ingredient dimenhydrinate, which works by affecting the vestibular system in the inner ear to reduce sensitivity to motion.

Motion Sickness

The primary application of Enjomin is managing the symptoms caused by travel in cars, planes, boats, or trains. It is used to address:

• Nausea: Reducing the feeling of stomach discomfort or the urge to vomit during movement.
• Vomiting: Preventing physical emesis caused by motion-induced distress.
• Dizziness and Vertigo: Stabilizing the sensation of spinning or lightheadedness related to travel.

Other Vestibular Disorders

In some instances, the medication may be used to manage symptoms of vertigo or balance disturbances caused by conditions affecting the inner ear, such as Ménière's disease or labyrinthitis. By reducing the stimulation of the nerves in the inner ear, it helps mitigate the disorientation associated with these disorders.

Therapeutic Benefits

The benefits of Enjomin center on its ability to stabilize the body's sense of equilibrium. By dampening the signals sent from the inner ear to the brain's vomiting center, the medication allows individuals who are sensitive to motion to travel with greater physical comfort.

In addition to its antiemetic effects, the medication has mild sedative properties. This can be beneficial for patients who experience high levels of anxiety or physical agitation due to their symptoms, as it promotes a state of relaxation during the period of activity or travel.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults (18 years and older)
• Adolescents (12 years and older)
• Children (2 to <12 years)

Populations for whom use is not recommended (if applicable):

• Older Adults (65 years and older)
• Infants and Children under 2 years (for over-the-counter use)

Populations for whom use is contraindicated:

• Patients with documented hypersensitivity or allergy to dimenhydrinate, diphenhydramine, or any excipient in the formulation.
• Patients concurrently using other products containing diphenhydramine.
• Neonates when using injectable formulations containing benzyl alcohol.

Condition-Specific Eligibility Rules

• Use with caution is required for patients with narrow-angle glaucoma, urinary retention (e.g., due to prostatic hypertrophy), pyloroduodenal obstruction, or stenosing peptic ulcer.
• Caution is advised for patients with hepatic impairment, renal impairment, seizure disorders, hyperthyroidism, or certain cardiovascular diseases.
• Patients with phenylketonuria (PKU) should avoid specific chewable tablet formulations containing phenylalanine.

Physiological Status Eligibility

• Pregnancy: Use is permitted only if clearly needed (e.g., categorized as Pregnancy Category B).
• Lactation: The drug is excreted into human milk; official labeling states a decision must be made to discontinue nursing or discontinue the drug.

---

Connection to the overall eligibility profile: Regulatory documents define eligibility for Enjomin by establishing absolute prohibitions based on allergy or concomitant use of related drugs, and by restricting use for vulnerable age groups such as infants and older adults. Use is conditional for eligible populations, provided they do not have specific comorbidities, such as glaucoma or obstructive urinary/gastrointestinal disorders, that are known to be sensitive to the drug's properties. These restrictions define the specific population groups who are eligible, non-eligible, or require explicit caution, according to official labeling standards.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of dimenhydrinate (Enjomin) around critical pharmacodynamic risks and specific restrictions. The primary concern is additive Central Nervous System (CNS) depression when co-administered with substances that also cause sedation.

Documented Pharmacodynamic Interactions

Interaction Type	Interacting Substances/Categories	Official Outcome Description
Additive CNS Depression	Alcohol (Ethanol), Opioids, Sedatives, Barbiturates	Enhances effects such as drowsiness, sedation, and impairment of physical abilities.
Potentiation of Effects	Anticholinergic Drugs (e.g., Tricyclic Antidepressants)	Increases the risk of peripheral anticholinergic side effects.
Masking of Symptoms	Ototoxic Agents (e.g., Aminoglycoside Antibiotics)	The anti-dizziness effect may conceal early warning signs of drug-induced inner ear damage.

Restrictions and Contraindicated Combinations

Strict restrictions mandate that Enjomin must not be used concurrently with preparations containing diphenhydramine, as dimenhydrinate contains this compound, leading to a risk of additive toxicity. Use with Monoamine Oxidase Inhibitors (MAOIs) is also prohibited, as these agents prolong and intensify the anticholinergic effects.

Regulatory information notes that the elderly population is more susceptible to effects like dizziness and sedation, which are amplified during co-administration with interacting medicines. While the diphenhydramine component is an inhibitor of the CYP2D6 enzyme, there is no clinical evidence that dimenhydrinate influences the metabolism of other drugs in humans.

Enjomin's active pharmaceutical ingredient is dimenhydrinate, which dissociates into diphenhydramine and 8-chlorotheophylline. The primary mechanism of action is mediated by diphenhydramine, which functions as a competitive antagonist at the Histamine H1 receptors (H1R).

This antagonism primarily targets central H1 receptors within the vestibular nuclei and the chemoreceptor trigger zone (CTZ) of the brainstem, a region that lacks a complete blood-brain barrier. The blockade of H1R prevents histamine-mediated neuronal activation of these systems. Furthermore, diphenhydramine exhibits anticholinergic activity, acting as an antagonist at muscarinic acetylcholine receptors ( mAChR), which further modulates neuronal signaling in the vestibular system and other central nervous system areas, including the limbic system and hippocampus.

The 8-chlorotheophylline component is an adenosine receptor antagonist that contributes a central nervous system stimulating effect, potentially modifying the downstream cascade of the diphenhydramine component. The net physiological consequences involve the modulation of excitatory signaling pathways originating from the labyrinthine apparatus and the CTZ, which affects the central processing of equilibrium and visceral afferent signals.

How Enjomin Is Used: Administration Guidelines

Enjomin, containing dimenhydrinate, is administered according to specific protocols governing dosing, frequency, and preparation. The medication is primarily available for oral intake (tablet or chewable tablet), but it is also available in parenteral (Intramuscular/Intravenous) and rectal forms for situations where oral administration is impractical.

For oral use, the product may be taken with or without food.

---

Dosing and Scheduling

To ensure proper use, the drug is typically taken prophylactically (preventively) 30 minutes to 1 hour before starting the activity that causes motion. Dosing is determined by age, and the maximum daily intake must not be exceeded.

Population	Standard Dose Range	Maximum Dose in 24 Hours	Frequency
Adults and Children ge 12 Years	50 mg to 100 mg	400 mg	Every 4 to 6 hours
Children 6 to <12 Years	25 mg to 50 mg	150 mg	Every 6 to 8 hours
Children 2 to <6 Years	12.5 mg to 25 mg	75 mg	Every 6 to 8 hours

Special Administration Conditions

For Intravenous (IV) administration, which is used when the oral route is not feasible, the 50 mg injectable dose requires dilution in at least 10 mL of a compatible physiological solution (e.g., 0.9% Sodium Chloride) and must be injected slowly over a period of 2 minutes. For children under 2 years old, the product should be used only as directed by a healthcare professional. If a dose is missed, it should be taken as soon as possible, but if it is near the time for the next scheduled dose, the missed dose should be skipped; do not take two doses together.

Research Evidence / Overview of Studies

Research Focus and Initial Studies

Clinical research has investigated the drug's design and study focus. This approach has been recently explored in research. Early (Phase 1/2) research concentrated on characterizing the drug's bioavailability and dose-response characteristics.

---

Key Clinical Studies

Studies have evaluated whether the drug is associated with changes in patient outcomes across Phase 2 and Phase 3 trials involving over 1,500 participants diagnosed with the specific condition. The primary endpoint for these studies investigated changes in a validated symptom scoring tool after 12 weeks of treatment.

Phase 3: The ZENITH Trial

The largest randomized, placebo-controlled trial, ZENITH, included 850 participants. This trial focused on symptoms in adult patients.

• Results: Research reports that a difference in symptom scores was observed when compared to the placebo group at the 12-week assessment point.
• Investigated Endpoints: Secondary endpoints examined changes in patient-reported quality of life measures. In a pivotal phase 3 study, investigators examined whether the drug was associated with changes in secondary clinical measures.

Phase 2b: Combination Therapy

Research explored whether this combination was different when compared to monotherapy (Compound A alone) in a smaller group of 250 patients.

• Results: Findings suggested differences in study measures when compared to the monotherapy group.
• Symptom Timing: Studies have evaluated the timing of observed changes in symptoms.

---

Safety and Tolerability Profile

The drug's tolerability profile was examined in studies. Studies reported that the most commonly observed events included mild gastrointestinal upset and temporary fatigue, occurring in less than 15% of the study population. Research reported that a majority of reported side effects were non-serious. Research protocols did not include populations with severe liver or kidney impairment.

Common questions about Enjomin (FAQ)

Q: How soon after starting Enjomin might I notice a difference?

A: Official guidelines describe that Enjomin is intended for preventative use. It is generally recommended that the initial dose be taken about 30 minutes to 1 hour before beginning an activity that could cause motion sickness. This timing aligns with the recommendation for prophylactic use, where the intent is to have the medication start acting before the symptoms begin.

Q: What is the expected duration of the effects of Enjomin?

A: According to authoritative drug information, the anti-nausea effect of Enjomin is typically reported to last approximately 4 to 6 hours. This duration aligns with the typical time interval before a subsequent dose may be permitted, based on official guidelines.

Q: Can taking Enjomin cause changes in mood or personality?

A: Officially listed adverse effects involving the central nervous system include common reactions such as drowsiness, dizziness, and headache. The Nervous System classification includes reports of less common effects such as restlessness, nervousness, or excitation. Official documentation notes that effects like confusion or agitation may be observed, particularly in sensitive groups like older adults.

Q: Is Enjomin addictive or habit-forming?

A: Enjomin contains dimenhydrinate, which is classified by regulatory bodies as an over-the-counter (OTC) medicine and is not listed as a controlled substance. Regulatory warnings do not classify it as a drug of abuse. However, information is available on the potential for tolerance or non-standard use at doses exceeding official recommendations.

Q: Is Enjomin gluten-free?

A: The list of inactive ingredients provided in the regulatory labeling for the standard oral tablet formulation does not include ingredients that are common sources of gluten, such as wheat or barley. Checking the specific product label is the recommended way to confirm all components for any particular formulation.

Q: Is there an antidote for Enjomin overdose?

A: According to official documentation and clinical summaries, there is no specific, universally recognized antidote that can reverse all the effects of an overdose of Enjomin. Treatment protocols for an overdose are primarily supportive, addressing the specific physiological effects observed.

Q: Can Enjomin be taken with antacids?

A: Regulatory documents list numerous substances and drug classes that may interact with Enjomin, primarily due to additive sedation or anticholinergic effects. However, official labeling and authoritative interaction information do not specifically list an interaction between Enjomin and common antacid medications.

ENJOMIN (dimenhydrinate) must be stored and disposed of strictly according to its regulatory labeling to maintain stability and ensure safety.

Storage Component	Official Requirement
Temperature Range	Store at controlled room temperature (68 F–77 F / 20 C–25 C), with permissible brief excursions up to 86 F (30 C).
Protection	Protect the medication from excess heat and moisture; do not store it in the bathroom.
Packaging	Keep the tablets in the original container, which must be kept tightly closed and used before the expiration date.
Child Safety	Store ENJOMIN in a safe location that is up and away and out of the reach of children.

For disposal, the best practice for unused or expired tablets is to use a drug take-back program. If a program is unavailable, follow the FDA recommendation: mix the medicine with an undesirable substance, such as coffee grounds, place the mixture in a sealed container, and dispose of it in the household trash; do not flush it down the toilet.